PBGENE-DMD has received Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA) enabling initiation of clinical trial site activation. PBGENE-DMD was previously granted FDA ...
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...
ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the World Muscle Society ...
ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.
- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy - - On track to file an IND and/or CTA by the end ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results